Non-Invasive Imaging in the Pharmaceutical Industry

Over recent years, whilst it is taking increased time and cost to get a new drug to market, productivity is declining. It is critical for the survival of the pharmaceutical industry, to both improve efficiency of the drug discovery and development process and to increase success rates, with better predictivity from preclinical to clinical investigation (Kola. 2008). Imaging provides unique tools to improve efficiency and predictivity.

[1]  J. Waterton,et al.  Reduced animal use in efficacy testing in disease models with use of sequential experimental designs. , 2000 .

[2]  Bengt Långström,et al.  Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.

[3]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.

[4]  P. Hockings.  Magnetic Resonance Imaging in Pharmaceutical Safety Assessment , 2006 .

[5]  J. Waterton,et al.  Evaluation of a magnetic resonance biomarker of osteoarthritis disease progression: doxycycline slows tibial cartilage loss in the Dunkin Hartley guinea pig , 2009, International journal of experimental pathology.

[6]  MRI studies of the neurotoxic effects of L-2-chloropropionic acid on rat brain. , 2001, Magnetic resonance imaging.

[7]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[8]  S. Farooqi.  Treating obesity: does antagonism of NPY fit the bill? , 2006, Cell metabolism.

[9]  F. Howe,et al.  Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. , 2004, Neoplasia.

[10]  Joanna Leadbetter,et al.  Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 , 2004, Clinical Cancer Research.

[11]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[12]  J. Fozard,et al.  Pulmonary edema induced by allergen challenge in the rat: Noninvasive assessment by magnetic resonance imaging , 2001, Magnetic resonance in medicine.

[13]  J. Waterton,et al.  Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. , 2007, Neoplasia.

[14]  S. Guichard,et al.  Abstract A225: The mTOR kinase inhibitor AZD8055 modulates 18F‐FDG uptake in vivo in the human glioma xenograft model U87‐MG , 2009 .

[15]  Bart Cornelissen,et al.  Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts , 2009, Journal of Nuclear Medicine.

[16]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[17]  F. Westwood,et al.  Characterisation of the guinea pig model of osteoarthritis by in vivo three-dimensional magnetic resonance imaging. , 2003, Osteoarthritis and cartilage.

[18]  H. G. Vogel,et al.  Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays , 2013, Springer Berlin Heidelberg.

[19]  P. Hockings,et al.  1H and hyperpolarized 3He MR imaging of mouse with LPS‐induced inflammation , 2009, Journal of magnetic resonance imaging : JMRI.